Detail

Basic Information Clinical Results Relationship Graph

Basic Information

Gene symbol	CD19	Synonyms	B4, CVID3	Type of gene	protein-coding
Chromosome	16	Map location	16p11.2	dbXrefs
Description	CD19 molecule

GTO ID	GTC0323
Trial ID	NCT02822326
Disease	Acute Lymphoblastic Leukemia
Altered gene	CD19
Therapeutic/Target gene	Target gene
Therapy	CAR-T cell
Treatment	1928zT2 T cell
Generation	3rd
Phase	Phase1
Recruitment status	Unknown
Title	Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia
Year	2016
Country	China
Company sponsor	Guangdong Provincial People's Hospital
Other ID(s)	No.GDREC2016198H

Vector information

Vector	lentivirus
Construct	scFv-CD28-TLR2-CD3ζ
Transgene/Inserted gene	19-28z-TLR2; CAR-linking FMC63-scFv; D28 transmembrane and endodomain; CD3ζ signaling domain; TIR domain (amino acid 639-784) of TLR2
Vector production method	Primary human T lymphocytes were isolated and collected, then stimulated with magnetic beads coated with anti-CD3/anti-CD28 antibodies (Miltenyi Biotec) at cell to bead ratio of 1 to 2. Approximately 72 h after activation, T cells were transfected with 19-28z-TLR2 lentiviral vector. These T cells were fed every 2 days with fresh media and used within 14 days of expansion

Clinical Result

Cohort 1

Administration route	infusion
Dosage	5E4~1E6 cells/kg, 10% on day 1, 30% on day 2, and 60% on day 3
Pts	3
Age	Child, Adult, Older_Adult
Lymph depletion	Yes
Outcome	3/3(CR)
Adverse reactions	1/3(cytokine release syndrome)
References	PMID: 29458388

Relationship Graph

Overview of Knowledge Graph